CTX131

BIOLOGICAL2 trials

Sponsors

CRISPR Therapeutics AG, CRISPR Therapeutics

Conditions

Acute Myeloid LeukemiaB Cell LymphomaCervical CarcinomaClear Cell Renal Cell CarcinomaEsophageal CarcinomaMalignant Pleural MesotheliomaPancreatic AdenocarcinomaT Cell Lymphoma

Phase 1

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

CompletedNCT05795595

CRISPR Therapeutics AGCervical Carcinoma, Clear Cell Renal Cell Carcinoma, Esophageal Carcinoma +2

Start: 2023-03-13End: 2025-09-18Updated: 2025-11-26

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

CompletedNCT06492304

CRISPR TherapeuticsAcute Myeloid Leukemia, B Cell Lymphoma, T Cell Lymphoma

Start: 2024-08-13End: 2026-03-11Updated: 2026-04-03

Related Papers

A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.

Journal of Clinical Oncology2024-06-017 citations